Technology
Health
Biotechnology

Sunesis

$1.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-10.48%) Today
+$0.09 (9.57%) After Hours

Why Robinhood?

You can buy or sell Sunesis and other stocks, options, ETFs, and crypto commission-free!

About

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Read More The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Employees
29
Headquarters
South San Francisco, California
Founded
1998
Market Cap
68.18M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
475.81K
High Today
$1.08
Low Today
$0.916
Open Price
$1.06
Volume
708.09K
52 Week High
$2.87
52 Week Low
$0.20

Collections

Technology
Health
Biotechnology
Therapy
Research And Development
Pharmaceutical
Medical
US

News

Seeking AlphaMay 8

Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q1 20189 Results - Earnings Call Transcript

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer Deepali Suri - Vice President, Clinical Operations Conference Call Participants Marc Frahm - Cowen and Company Hartaj Singh - Oppenheimer Operator Good afternoon, ladies and gentlemen and welcome to the Q1 201...

446
Yahoo FinanceMay 8

Sunesis: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Sunesis Pharmaceuticals Inc. (SNSS) on Wednesday reported a loss of $5.9 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 10 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share. In the final minutes of trading on Wednesday, the company's shares hit $1.45. A year ago, they were tradi...

189
NasdaqMay 8

Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

Phase 1b/2 Trial of Vecabrutinib Advances into 200 mg Cohort Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2019. Loss from operations for the three months ended March 31, 2019 was $5.7 million. As of March 31, 2019, cash and cash equivalents totaled $24.8 million. "We continue our focus on the execution of th...

157

Earnings

-$0.43
-$0.32
-$0.21
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.